Isotechnika to participate in Friedman Billings Ramsey Technology and Growth investor conference
Isotechnika Inc. Trades on Toronto Stock Exchange - (TSX:ISA)
EDMONTON, AB, May 29 /CNW/ - Isotechnika Inc. will be participating in
the 7th Annual Technology and Growth Conference hosted by Freidman, Billings
and Ramsey. The conference is being held on May 28 - 29, 2003 in New York.
Dr. Robert Foster, Chairman and CEO of Isotechnika will be presenting an
update on the Company's clinical and corporate activities today at 10:00 a.m.
EST.
More than 100 North American public and private technology and healthcare
companies will be making presentations at this exclusive investor conference.
Conference participation is by invitation only.
Freidman, Billings and Ramsey, the conference host, is widely considered
to be among the top 10 lead-managed equity underwriters and among the leading
research-driven national brokerages in the United States.
"It is a great privilege for Isotechnika to have been invited to
participate in this prestigious investor conference," stated Dr. Foster. "Our
participation reflects a growing international recognition of our company, its
validated research platform, its proprietary technology and its sharp focus in
the area of immunosuppression."
About Isotechnika Inc.
----------------------
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta. Drawing upon its expertise in medicinal
chemistry and immunology, the Company is focused on the discovery and
development of novel immunosuppressive therapeutics which are safer than
currently available treatments. Its entrepreneurial management and world-class
team of scientists are building a pipeline of immunosuppressive drug
candidates for use in the prevention of organ rejection in transplantation and
in the treatment of autoimmune diseases. Its lead compound, ISA247, a multi-
platform drug, has progressed through discovery, pre-clinical and Phase II
human clinical trials in less than six years. The Company has recently
completed a Phase II human clinical trial for psoriasis with very promising
results, and is currently in the final stages of a Phase II human clinical
trial in renal transplantation. Isotechnika looks to become the market leader
in immunosuppressant therapy; an established market for drugs of this class is
in excess of 2.2 billion USD per year globally. In April 2002, Isotechnika
signed a major agreement with Roche for the global co-development and
commercialization of Isotechnika's ISA247. Isotechnika Inc. is an S&P/TSX
Composite Index company publicly traded under the symbol ISA. More information
on Isotechnika can be found at www.isotechnika.com. |
